home
portfolio
team
careers
contact
investor portal
home
portfolio
team
careers
contact
investor portal
Nextech Invest
Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors
Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors
Post navigation
Previous Post
Previous
EQRx Appoints Jami Rubin as Chief Financial Officer and Kent Rogers as Chief Customer Officer
Next Post
Next
Turning Point Therapeutics Initiates Global Phase 1/2 Forge-1 Clinical Study of TPX-0131, a Next-Generation ALK Inhibitor